© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
FDA Approves Moderna's mRESVIA, First mRNA Vaccine Against RSV, for Adults Aged ≥60 Years
June 03, 2024
mRESVIA is Moderna's second mRNA-based vaccine and will be shipped in prefilled syringes, a desirable feature that could save clinical time, prevent errors.
Surya Bhatt, MD, MSPH, Reports the Pivotal Phase 3 Findings for Dupilumab as Add-On Treatment for COPD
May 31, 2024
The dual interleukin-4, 13 inhibitor reduced COPD exacerbation rates by as much as 34% for individuals with COPD with type 2 inflammation, Bhatt explains.
FDA Decision on Dupilumab for COPD Pushed Back to September 2024
May 31, 2024
FDA has no concerns about the "approvability" of dupilumab for the new indication but needs additional time to review phase 3 data it requested early in May.
Primary Care Needs Training on Menopausal Issues, Treatment Options, says Women's Midlife Health Expert
May 30, 2024
Primary care clinicians are essential to maximizing evidence-based midlife care for women, according to Professor of Obstetrics & Gynecology JoAnn Pinkerton, MD.
Premenstrual Disorders May Increase Suicide Risk, Especially Among Young Women, Study Warns
May 29, 2024
The risk of mortality was not higher for women with vs without PMD overall but was particularly elevated for young women and for suicide across age of PMD diagnosis.
Elinzanetant Outcomes from the OASIS 1 and 2 Phase 3 Trials: A Read Out with Lead Investigator JoAnn Pinkerton, MD
May 29, 2024
The novel dual neurokinin-1,3 antagonist reduced VMS after just 1 week of treatment, Pinkerton said, and improved sleep and quality of life, as well. Hear more.
Plozasiran, an Investigational RNAi Therapy, Reduces Triglyceride Levels in Adults with Mixed Hyperlipidemia
May 28, 2024
Plozasiran, in the phase 2b MUIR trial, significantly reduced triglyceride and triglyceride rich lipoprotein levels through targeted action against APOC3.
Semaglutide Significantly Reduces Risk of Renal Events, MACE, Mortality in People with CKD, T2D in Final FLOW Trial Findings
May 24, 2024
The pluripotent GLP-1 mimetic reduced risk for renal disease endpoints by 24% and MACE by 18% plus significantly retarded decline in eGFR vs placebo, study authors reported.
US Drug Overdose Deaths Declined in 2023 for the First Time in 5 Years, CDC Reports
May 22, 2024
The 3% decline in 2023 compared with 2022 is "heartening news," CDC's Houry says, but the mission is far from accomplished.
Find and Treat Asthma and COPD: All Interventions Make a Difference, Study Concludes
May 22, 2024
Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.